Trials / Completed
CompletedNCT02925221
Canadian Medical Assessment of JINARC™ Outcomes Registry
Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 530 (actual)
- Sponsor
- Otsuka Canada Pharmaceutical Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with JINARC™ (tolvaptan)
Conditions
Timeline
- Start date
- 2016-02-26
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2016-10-05
- Last updated
- 2026-01-07
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02925221. Inclusion in this directory is not an endorsement.